SRC
GILD icon

Sage Rhino Capital’s Gilead Sciences GILD Stock Holding History

Sage Rhino Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$648K Buy
5,127
+7
+0.1% +$922 0.1% 132
2026
Q1 		$714K Sell
5,120
-1,493
-23% -$209K 0.13% 115
2025
Q4 		$812K Sell
6,613
-787
-11% -$95.6K 0.15% 113
2025
Q3 		$821K Buy
7,400
+5,041
+214% +$573K 0.16% 108
2025
Q2 		$262K Buy
2,359
+73
+3% +$7.77K 0.06% 195
2025
Q1 		$256K Buy
2,286
+26
+1% +$2.68K 0.06% 190
2024
Q4 		$209K Buy
+2,260
New +$203K 0.05% 237

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sage Rhino Capital's GILD Position: Q2 2026 in Review

Sage Rhino Capital increased its Gilead Sciences (GILD) stake by 0.14% in Q2 2026, buying an estimated $922 and bringing the position to 5,127 shares worth $648K. The position accounts for 0.1% of the portfolio, ranked #132.

Sage Rhino Capital first reported a position in GILD in Q4 2024 and has held it in 7 quarters since. The position peaked at $821K in Q3 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Sage Rhino Capital held 5,127 shares of Gilead Sciences worth $648K as of Q2 2026.
  • Sage Rhino Capital bought 7 Gilead Sciences shares in Q2 2026, an estimated $922.
  • Gilead Sciences made up 0.1% of Sage Rhino Capital's portfolio in Q2 2026, its #132 holding.
  • Sage Rhino Capital first reported a position in Gilead Sciences in Q4 2024 and has held it in 7 quarters since.
  • Sage Rhino Capital's Gilead Sciences position peaked at $821K in Q3 2025.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Sage Rhino Capital's 13F filing for Q2 2026, filed 3 Aug 2026.